- Trial phase
- unknown (no public trial record found)
- Time to market
- unknown, no clinical trial or development stage could be verified
- Why 1/10
- No scheduled catalyst of any kind can be identified for ALN-5288: the code appears in no web coverage retrievable this session and in no local trial/FDA/catalyst/press record, so there is no dated binary to anchor a share-price move, per the rubric an unverifiable, apparently early/unannounced program with nothing scheduled scores at the bottom of the 0-2 band.
Treat any claim about this specific drug as unverified, the stock's near-term drivers are other programs (e.g., the April 2026 cemdisiran NDA submitted by Regeneron), not ALN-5288.
Price Chart
Executive Summary
ALN-5288 is an Alnylam Pharmaceuticals development code with no verifiable public profile. SecBot's internal data corroborates the ticker (ALNY = Alnylam Pharmaceuticals, Inc., confirmed via SEC filings) but contains zero references to ALN-5288 across trials, FDA actions/catalysts, press releases, and events. Alnylam is a large, well-covered RNAi company (stock ~$205.52 as of 2026-07-31; analyst consensus buy with a mean target of ~$427.61), but that valuation rests on its marketed and later-stage programs, not on this unverified code. Rating is neutral because there is nothing grounded to be bullish or bearish about for this specific drug.
How It Works
Unknown and unverified. Alnylam's core platform is RNAi therapeutics (drugs that silence disease-causing genes), but no source retrieved this session describes what ALN-5288 targets or how it works, it may be an early, undisclosed candidate, or the code may not correspond to a real public program.
Trial Status
No verifiable trial status. Searches of SecBot's ingested ClinicalTrials.gov records, FDA catalyst data, and press/events tables returned zero matches for "ALN-5288" or "5288" linked to Alnylam. The only "5288" match anywhere was an unrelated GSK hepatitis B vaccine trial (NCT03866187).
The Two-Sided Case
Upcoming Catalysts
- None identifiable for ALN-5288 specifically.
- Company-level context (not this drug): Regeneron submitted an NDA for Alnylam-partnered cemdisiran in generalized myasthenia gravis on 2026-04-30, a real, dated regulatory event for the company.
- Alnylam earnings/Q2 report: 8-K earnings release filed 2026-07-30, watch management commentary for any mention of new early-stage ALN codes.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report